T2 Biosystems Inc Revenue Growth Rates (TTOO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
T2 Biosystems Inc   (NASDAQ: TTOO)
 

TTOO's Revenue Growth by Quarter and Year

T2 Biosystems Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TTOO Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September 1.99
2nd Quarter June 1.95
1st Quarter March 2.06
FY 6.00

TTOOs Annual Revenue
T2 Biosystems Inc 's Revenue in the fiscal year 2023 $ 7.19 millions
T2 Biosystems Inc 's Revenue in the fiscal year 2022 $ 22.31 millions
T2 Biosystems Inc 's Revenue in the fiscal year 2021 $ 28.06 millions
T2 Biosystems Inc 's Revenue in the fiscal year 2020 $ 18.13 millions
T2 Biosystems Inc 's Revenue in the fiscal year 2019 $ 8.34 millions




TTOO Revenue third quarter 2024 Y/Y Growth Comment
T2 Biosystems Inc achieved in the third quarter 2024, above Company average Revenue growth of 35.03% year on year, to $ 1.99 millions.

Looking into third quarter 2024 results within Medical Equipment & Supplies industry 123 other companies have achieved higher Revenue growth. While T2 Biosystems Inc ' s Revenue rise of 35.03% ranks overall at the positon no. 2765 in the third quarter 2024.


TTOO Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - -69.34 % -21.49 % -10.4 %
3rd Quarter September 35.03 % -60.05 % -50.47 % 41.52 %
2nd Quarter June -0.51 % -66.84 % -11.66 % 162.35 %
1st Quarter March -0.96 % -71.23 % 3.88 % 172.94 %
FY   - -67.76 % -20.53 % -

Financial Statements
T2 Biosystems Inc 's third quarter 2024 Revenue $ 1.99 millions TTOO's Income Statement
T2 Biosystems Inc 's third quarter 2023 Revenue $ 1.47 millions Quarterly TTOO's Income Statement


TTOO Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 14.29 % 48.91 % -6.06 %
3rd Quarter September 1.79 % -25 % -37.73 % 11.06 %
2nd Quarter June -5.34 % -5.77 % -18.26 % -3.88 %
1st Quarter March 22.62 % -62.04 % 3.58 % -10.65 %
FY (Year on Year)   - -67.76 % -20.53 % -


Back to TTOO Growth rate Comparisons >> Back to TTOO Growth rate Comparisons >>


Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #124
Healthcare Sector #401
Overall #2765

Revenue Y/Y Growth Statistics
High Average Low
171.09 % 32.67 % -66.04 %
(Jun 30 2021)   (Mar 31 2024)
Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #124
Healthcare Sector #401
Overall #2765
Revenue Y/Y Growth Statistics
High Average Low
171.09 % 32.67 % -66.04 %
(Jun 30 2021)   (Mar 31 2024)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

T2 Biosystems Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
200 % 11.53 % -100 %
(Jun 30 2015)  


TTOO's III. Quarter Q/Q Revenue Comment
T2 Biosystems Inc achieved in the III. Quarter 2024 below company average Revenue growth of 1.79% quarter on quarter, to $ 1.99 millions.

Although the III. Quarter 2024 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -25% growth in the III. Quarter a year ago

Within Medical Equipment & Supplies industry 115 other companies have achieved higher Revenue quarter on quarter growth. While T2 Biosystems Inc 's Revenue growth quarter on quarter, overall rank is 1696.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #116
Healthcare Sector #345
Overall #1696
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #116
Healthcare Sector #345
Overall #1696
Revenue Q/Q Growth Statistics
High Average Low
200 % 11.53 % -100 %
(Jun 30 2015)  


TTOO's III. Quarter Q/Q Revenue Comment
T2 Biosystems Inc achieved in the III. Quarter 2024 below company average Revenue growth of 1.79% quarter on quarter, to $ 1.99 millions.

III. Quarter 2024 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -25% in the III. Quarter a year ago.

Within Medical Equipment & Supplies industry 115 other companies have achieved higher Revenue quarter on quarter growth. While T2 Biosystems Inc 's Revenue growth quarter on quarter, overall rank is 1696.


T2 Biosystems Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)
Cumulative Revenue 12 Months Ending $ 7.68 $ 7.16 $ 7.18 $ 7.19 $ 11.00
Y / Y Revenue Growth (TTM) -30.19 % -45.74 % -58.15 % -67.75 % -53.8 %
Year on Year Revenue Growth Overall Ranking # 3798 # 3329 # 0 # 0 # 3113
Seqeuential Revenue Change (TTM) 7.16 % -0.17 % -0.24 % -34.59 % -16.7 %
Seq. Revenue Growth (TTM) Overall Ranking # 2765 # 3136 # 0 # 0 # 2980


Cumulative Revenue growth Comment
T2 Biosystems Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2024. If the fiscal year would end in Sep 30 2024, T2 Biosystems Inc 's annual Revenue fall would be -30.19% year on year to $8 millions.

In the Healthcare sector 525 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3329 to 3798.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 124
Healthcare Sector # 526
Overall # 3798

Revenue TTM Y/Y Growth Statistics
High Average Low
171.09 %
 29.55 %
-67.75 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 124
Sector # 401
S&P 500 # 2765
Cumulative Revenue growth Comment
T2 Biosystems Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2024. If the fiscal year would end in Sep 30 2024, T2 Biosystems Inc 's annual Revenue drop would be -30.19% year on year to $8 millions.

In the Healthcare sector 525 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3329 to 3798.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 124
Healthcare Sector # 526
Overall # 3798

Revenue TTM Y/Y Growth Statistics
High Average Low
171.09 %
29.55 %
-67.75 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 124
Sector # 401
S&P 500 # 2765




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TTOO's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2024
Eton Pharmaceuticals Inc 60.89%$ 60.893 millions
Ginkgo Bioworks Holdings Inc 60.65%$ 60.646 millions
Nuo Therapeutics Inc 59.73%$ 59.727 millions
Cue Biopharma Inc 58.86%$ 58.857 millions
Ovid Therapeutics Inc 58.76%$ 58.756 millions
Fate Therapeutics Inc 58.13%$ 58.128 millions
Ligand Pharmaceuticals Incorporated57.64%$ 57.637 millions
Provectus Biopharmaceuticals Inc 57.38%$ 57.379 millions
Innoviva Inc 52.28%$ 52.283 millions
Esperion Therapeutics Inc 52.00%$ 51.997 millions
Arcus Biosciences Inc 50.00%$ 50.000 millions
Lucid Diagnostics Inc 49.68%$ 49.681 millions
Nexalin Technology Inc 49.51%$ 49.506 millions
Stoke Therapeutics Inc 47.94%$ 47.944 millions
Rhythm Pharmaceuticals Inc 47.76%$ 47.756 millions
Zai Lab Limited47.72%$ 47.722 millions
Corcept Therapeutics Inc47.69%$ 47.690 millions
Harvard Apparatus Regenerative Technology Inc 47.50%$ 47.500 millions
Invo Fertility Inc 47.01%$ 47.006 millions
Ceribell Inc 46.51%$ 46.508 millions
Genedx Holdings Corp 44.26%$ 44.255 millions
Harrow Inc 43.98%$ 43.982 millions
Electrocore Inc 43.94%$ 43.944 millions
Puma Biotechnology Inc 43.53%$ 43.528 millions
Ufp Technologies Inc 43.45%$ 43.447 millions
Avita Medical Inc 43.25%$ 43.247 millions
Scilex Holding Company42.69%$ 42.691 millions
Ultragenyx Pharmaceutical Inc 42.27%$ 42.265 millions
Sunshine Biopharma Inc 41.59%$ 41.585 millions
Igc Pharma Inc 41.58%$ 41.581 millions


About T2 Biosystems Inc Revenue Growth Rates (TTOO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: T2 Biosystems Inc (CIK 1492674).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-24-126996
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: T2 Biosystems Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.